Skip to main content
Clinical Trials/NCT04123431
NCT04123431
Recruiting
Not Applicable

A Prospective UK Multi-Centre Post Market Clinical Follow-up Study of the JRI Orthopaedic ACE Acetabular Cup System

JRI Orthopaedics1 site in 1 country225 target enrollmentJune 6, 2023
ConditionsHip Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hip Disease
Sponsor
JRI Orthopaedics
Enrollment
225
Locations
1
Primary Endpoint
Oxford Hip Score
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, and involves replacing both the hip ball and socket. Its goal is to provide pain relief, allowing the person to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has a H-A.C. coating to promote ossoeintegration of the device within the host bone. To increase the surgeons choice and thus suitability for the patient, there is the option of 3 different socket liners (ceramic, polymer or dual mobility).

To ensure maximum safety and performance of medical devices surveillance of the device should be carried out over the devices lifetime. This study is a 10 year surveillance study to assess the clinical, functional and radiological outcomes of the CE-marked ACE Acetabular Cup System. This is done by examining patient outcomes through questionnaires, reviews of X-rays and complications by patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.

Registry
clinicaltrials.gov
Start Date
June 6, 2023
End Date
November 1, 2035
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
JRI Orthopaedics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients deemed suitable for elective primary THR, as per indications in the IFU.
  • Male or female, 18 years or older.

Exclusion Criteria

  • Patients who are unable to provide written informed consent.
  • Patients deemed unsuitable for THR, as per contra-indications in the IFU.
  • Patients indicated for THR as a result of trauma (i.e. neck of femur fracture).
  • Patients who are pregnant (exclusion criteria for THR in general).
  • Patients receiving implants other than the approved combination, i.e. an ACE Acetabular Cup System with a JRI femoral stem and head.
  • Patients who are unable to comply with the protocol.

Outcomes

Primary Outcomes

Oxford Hip Score

Time Frame: 3 years post-op

A patient completed functional score to assess pain and function of the affected hip joint. Score range: 0 (worse) to 48 (best)

Secondary Outcomes

  • Radiological Assessment(1 year, 5 years and 10 years post-op)
  • Oxford Hip Score(6 months, 1 year, 5 years, 7 years and 10 years post-op)
  • EQ-5D-5L(6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op)
  • Modified Harris Hip Score(6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op)
  • Implant Survivorship(6 months, 1 year, 3 years, 5 years, 7 years and 10 years post-op)

Study Sites (1)

Loading locations...

Similar Trials